*Draft Guidance on Lisinopril*

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

**Active ingredient:** Lisinopril

**Form/Route:** Tablets/Oral

**Recommended studies:** 2 studies

1. **Type of study:** Fasting  
   **Design:** Single-dose, two-treatment, two-period crossover *in vivo*  
   **Strength:** 40 mg  
   **Subjects:** Normal healthy males and females, general population.  
   **Additional Comments:** Females must have a negative baseline pregnancy test within 24 hours prior to receiving the drug. Females should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study.

2. **Type of study:** Fed  
   **Design:** Single-dose, two-treatment, two-period crossover *in vivo*  
   **Strength:** 40 mg  
   **Subjects:** Normal healthy males and females, general population.  
   **Additional Comments:** Please see comments above.

**Analytes to measure (in appropriate biological fluid):** Lisinopril in plasma.

**Bioequivalence based on (90% CI):** Lisinopril

**Waiver request of in-vivo testing:** 2.5 mg, 5 mg, 10 mg, 20 mg, and 30 mg, based on acceptable (i) bioequivalence studies on the 40 mg strength, and (ii) proportional similarity of the formulations and (iii) acceptable in vitro dissolution testing of all strengths.

**Dissolution test method and sampling times:**

Please note that a [Dissolution Methods Database](http://www.fda.gov/cder/ogd/index.htm) is available to the public at the OGD website at [http://www.fda.gov/cder/ogd/index.htm](http://www.fda.gov/cder/ogd/index.htm). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

*Recommended Jan 2008*